Alzamend Neuro, Inc.
ALZN
$0.67
-$0.04-5.63%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.59% | -48.52% | -55.54% | -53.10% | -43.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -66.04% | -61.53% | -51.99% | -33.17% | -19.73% |
| Operating Income | 66.04% | 61.53% | 51.99% | 33.17% | 19.73% |
| Income Before Tax | 65.92% | 61.42% | 51.89% | 33.14% | 19.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.92% | 61.42% | 51.89% | 33.14% | 19.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.92% | 61.42% | 51.89% | 33.14% | 19.69% |
| EBIT | 66.04% | 61.53% | 51.99% | 33.17% | 19.73% |
| EBITDA | 66.34% | 61.77% | 52.24% | 33.41% | 19.91% |
| EPS Basic | 83.53% | 71.28% | 54.62% | 35.19% | 23.16% |
| Normalized Basic EPS | 83.61% | 71.34% | 54.62% | 35.19% | 23.18% |
| EPS Diluted | 83.53% | 71.28% | 54.62% | 35.19% | 23.16% |
| Normalized Diluted EPS | 83.61% | 71.34% | 54.62% | 35.19% | 23.18% |
| Average Basic Shares Outstanding | 294.83% | 118.23% | 8.47% | 4.07% | 4.79% |
| Average Diluted Shares Outstanding | 294.83% | 118.23% | 8.47% | 4.07% | 4.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |